Why the study?
Does acetylsalicylic acid improve outcomes in the primary and secondary prevention of cardiovascular diseases?
Does acetylsalicylic acid improve outcomes in the primary and secondary prevention of cardiovascular diseases?
This review summarizes the efficacy, safety, and benefit-risk ratio of acetylsalicylic acid for primary and secondary cardiovascular prevention according to current guidelines.
Supports guideline-directed aspirin use in secondary prevention; leaves primary prevention thresholds open to individualized reassessment.
Acetylsalicylic acid (ASA) use in the primary and secondary prevention of cardiovascular diseases is focused. Mode of ASA disaggregation action is discussed. Data of randomized controlled trials on ASA efficacy and safety in primary and secondary prevention are presented. The main groups of patients who are required the ASA prevention according to current clinical guidelines are indicated. ASA benefit-risk ratio, as well as ways to improve the safety of antiplatelet therapy are presented, including use of enteric-soluble ASA forms.
No takes yet. Share an insight, caveat, or question.
Толпыгина et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: